Clinical Trial Update: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma [Phase 3]

View source ↗

Summary

This update describes a Phase 3 trial evaluating BCD-217 (Nurulimab + Proglolimab) followed by anti-PD-1 therapy versus anti-PD-1 monotherapy as first-line trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BCD-217 (Nurulimab + Proglolimab)

Snippet

Sponsor: Biocad | Conditions: Melanoma, Melanoma (Skin) | Phase 3 | Status: ACTIVE_NOT_RECRUITING